References
- Smith R. Improving the management of chronic disease. BMJ. 2003;7405:12.
- L. Jerlvall TP. IT stöd i Landstingen—Inventering på uppdrag av SLIT gruppen; 2006. http://213.180.94.156/dokument/publikationer_och_rapporter/rappoort_systeminventuring_ver_1.0.pdf. (Accessed January 5, 2012)
- de Lusignan S, van Weel C. The use of routinely collected computer data for research in primary care: opportunities and challenges. Fam Pract. 2006;2:253–63.
- The Canadian Primary Care Sentinel Surveillance Network. Available at: http://www.cpcssn.ca/cpcssn/home-e.asp. (Accessed January 5, 2012)
- DARTNet. University of Colorado Department of Family Medicine. Available at: http://www.dartnet.info/. (Accessed January 5, 2012)
- Netherlands Information Network of General Practice. Available at: http://www.nivel.nl/oc2/page.asp?PageID = 8496&path =/Startpunt/NIVEL international/About NIVEL. (Accessed January 5, 2012)
- The Swedish National Diabetes Register (NDR). Available at: https://www.ndr.nu/ndr2/. (Accessed January 5, 2012)
- The BEACH project: Bettering the Evaluation and Care of Health. Australian General Practice Statistics and Classification Centre. Available from: http://www.fmrc.org.au/beach.htm. (Accessed January 5, 2012)
- Ringborg A, Martinell M, Stalhammar J, Yin DD, Lindgren P. Resource use and costs of type 2 diabetes in Sweden—estimates from population-based register data. Int J Clin Pract. 2008;5:708–16.
- Pettersson B, Ambegaonkar B, Sazonov V, Martinell M, Stalhammar J, Wandell P. Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). BMC Public Health. 2010;1:737.
- Ringborg A, Lindgren P, Martinell M, Yin DD, Schon S, Stalhammar J. Prevalence and incidence of type 2 diabetes and its complications 1996–2003—estimates from a Swedish population-based study. Diabet Med. 2008;10:1178–86.
- Ringborg A, Lindgren P, Yin DD, Martinell M, Stalhammar J. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes Metab. 2010;3:198–203.
- Lindgren P, Borgstrom F, Stalhammar J, Alemao E, Yin DD, Jonsson L. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil. 2005;6:530–4.
- Lindgren P, Borgstrom F, Stalhammar J, Alemao E, Jonsson L. Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. Int J Clin Pract. 2007;8:1410–14.
- Ringborg A, Yin DD, Martinell M, Stalhammar J, Lindgren P. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil. 2009;16:576–82.
- Carlsson A, Borgstrom F, Stalhammar J, Alemao E, Yin DD, Jonsson L. Cost of care for patients treated with lipid-lowering drugs. Pharmacoeconomics. 2004;22 (Suppl 3):25–35.
- Kjeldsen SE, Stalhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens. 2009;4:263–73.
- Liljeqvist G, Staff M, Puech M, Blom H, Torvaldsen S. Automated data extraction from general practice records in an Australian setting: Trends in influenza-like illness in sentinel general practices and emergency departments. BMC Public Health. 2011;11:435.